title: Current concepts and issues in the management of regurgitation of infants: a reappraisal. Management guidelines from a working party.
abstract: Regurgitation in infants is a common problem. Recent issues, such as the increased risk of sudden infant death in the prone sleeping position, the finding of persisting occult gastro-oesophageal reflux with feed thickeners, and the increasing awareness of the cost-benefit ratio of medications may challenge the currently recommended management approach. A round table was organized to elaborate on the impact of (i) the pro supine sleeping campaigns in relation to sudden infant death and (ii) advancement in medical treatment on therapeutic strategies in regurgitating infants. The participants were opinion leaders from Europe and North America (Belgium, Canada, France, UK, Italy, Switzerland and The Netherlands). The importance of parental reassurance is stressed. As a consequence of the supine sleeping campaigns aiming to decrease the incidence of sudden infant death syndrome, the "prone elevated sleeping position" is no longer advised as a first-line therapeutic approach, although it is still recommended in "complicated reflux". It is emphasized that milk thickeners are an adequate therapeutic tool for regurgitation, but not in reflux disease. According to the literature, the efficacy of (alginate )antacids, although very popular in some countries, is questionable. These recommendations will be of interest to first-line paediatricians, since about 40% of their patients, according to the literature, present because of regurgitation.
authors.affiliation: Vrije Universiteit Brussel, Belgium.
authors.forename: Y
authors.initials: Y
authors.lastname: Vandenplas
authors.forename: D
authors.initials: D
authors.lastname: Belli
authors.forename: P H
authors.initials: PH
authors.lastname: Benhamou
authors.forename: S
authors.initials: S
authors.lastname: Cadranel
authors.forename: J P
authors.initials: JP
authors.lastname: Cezard
authors.forename: S
authors.initials: S
authors.lastname: Cucchiara
authors.forename: C
authors.initials: C
authors.lastname: Dupont
authors.forename: C
authors.initials: C
authors.lastname: Faure
authors.forename: F
authors.initials: F
authors.lastname: Gottrand
authors.forename: E
authors.initials: E
authors.lastname: Hassall
authors.forename: H S
authors.initials: HS
authors.lastname: Heymans
authors.forename: C M
authors.initials: CM
authors.lastname: Kneepkens
authors.forename: B K
authors.initials: BK
authors.lastname: Sandhu
mesh_terms: D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D000932:Antiemetics / Q000627:therapeutic use; D020117:Cisapride; D005764:Gastroesophageal Reflux / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D007223:Infant; D007225:Infant Food; D008787:Metoclopramide / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D016684:Prone Position
chemical_list: D000897:Anti-Ulcer Agents; D000932:Antiemetics; D010880:Piperidines; D008787:Metoclopramide; D020117:Cisapride